Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.

[1]  Ping Chen,et al.  Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity. , 2004, Journal of medicinal chemistry.

[2]  Ping Chen,et al.  Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck). , 2003, Bioorganic & medicinal chemistry letters.

[3]  M. Dougados,et al.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.

[4]  A. Doweyko,et al.  Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[5]  S. Ward,et al.  Inhibitors of p56lck: assessing their potential as tools for manipulating T-lymphocyte activation , 2001 .

[6]  M. Šuša,et al.  Tyrosine kinase src inhibitors: potential therapeutic applications. , 2000, Drug news & perspectives.

[7]  A. DeFranco,et al.  Fcγ Receptor–Mediated Phagocytosis in Macrophages Lacking the Src Family Tyrosine Kinases Hck, Fgr, and Lyn , 2000, The Journal of experimental medicine.

[8]  D. Boschelli,et al.  Small molecule inhibitors of Src family kinases , 2000 .

[9]  L. Toledo,et al.  Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.

[10]  C. Damsky,et al.  Impaired integrin-mediated signal transduction, altered cytoskeletal structure and reduced motility in Hck/Fgr deficient macrophages. , 1999, Journal of cell science.

[11]  K. Rajewsky,et al.  From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. , 1999, Immunity.

[12]  W. Denny,et al.  Tyrosine Kinase Inhibitors. 14. Structure−Activity Relationships for Methyl- amino-Substituted Derivatives of 4-[(3-Bromophenyl)amino]-6-(methylamino)- pyrido[3,4-d]pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors for the EGF Family of Growth Facto , 1998 .

[13]  G. Firestein,et al.  T cells in arthritis , 1998 .

[14]  W. Denny,et al.  Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. , 1997, Journal of medicinal chemistry.

[15]  W. Denny,et al.  Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. , 1997, Journal of medicinal chemistry.

[16]  Hiroto Yamaguchi,et al.  Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.

[17]  A. Weiss,et al.  The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. , 1994, Annual review of immunology.

[18]  R. Perlmutter,et al.  A dominant‐negative transgene defines a role for p56lck in thymopoiesis. , 1993, The EMBO journal.

[19]  John Calvin Reed,et al.  Effects of p56lck deficiency on the growth and cytolytic effector function of an interleukin-2-dependent cytotoxic T-cell line , 1992, Molecular and cellular biology.

[20]  Arthur Weiss,et al.  Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor , 1992, Cell.

[21]  A. Wakeham,et al.  Profound block in thymocyte development in mice lacking p56lck , 1992, Nature.

[22]  G. Muir,et al.  66. Reactions of certain thiazoles and glyoxalines with picryl chloride and 2 : 4-dinitrochlorobenzene , 1942 .